Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 4/20 | 0.62 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.47 |
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
| ▸ | FNTB | P49356 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461665 | 0.86 | KMT2A (0.64) | GGPS1FNTAFNTBKMT2APGGT1B | |
| SCHEMBL14151883 | 0.83 | GGPS1 (0.61) | GGPS1FNTAFNTBKMT2A | |
| SCHEMBL14151882 | 0.83 | GGPS1 (0.61) | GGPS1FNTAFNTBKMT2A | |
| SCHEMBL5373407 | 0.77 | KMT2A (0.50) | BTN3A1FNTAFNTBMAPTALDH1A1 | |
| SCHEMBL10002547 | 0.77 | BTN3A1 (1.00) | BTN3A1FNTAFNTB | |
| SCHEMBL11021028 | 0.77 | KMT2A (0.50) | BTN3A1FNTAFNTBMAPTALDH1A1 | |
| SCHEMBL23924906 | 0.77 | KMT2A (0.50) | BTN3A1FNTAFNTBMAPTALDH1A1 | |
| SCHEMBL24835115 | 0.77 | BTN3A1 (1.00) | BTN3A1FNTAFNTB | |
| SCHEMBL23925025 | 0.77 | KMT2A (0.50) | BTN3A1FNTAFNTBMAPTALDH1A1 | |
| SCHEMBL25220642 | 0.77 | KMT2A (0.50) | BTN3A1FNTAFNTBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11116774-B2 | Modulators of toll-like receptors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11116774-B2 | Modulators of toll-like receptors for the treatment of HIV | TLR7, TLR3, TLR6 | BTN3A1 4435/4885GGPS1 3304/4885FNTA 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.